^
    Back
    Association details:
    Biomarker:HHLA2 positive
    Cancer:Solid Tumor
    Drug:NPX267 (KIR3DL3 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    SITC 2022
    Title:

    489 NPX267, a first-in-class monoclonal antibody targeting KIR3DL3, blocks HHLA2-mediated immunosuppression and potentiates T and NK cell-mediated antitumor immunity

    Published date:
    11/08/2022
    Excerpt:
    NPX267 treatment augmented the ability of human NK cell lines and primary NK cells to kill HHLA2 + tumor cells in vitro….NPX267, a first-in-class KIR3DL3 blocking antibody, potentiates anti-tumor immunity against HHLA2 + tumors and may represent a promising approach to treat certain cancers.
    DOI:
    10.1136/jitc-2022-SITC2022.0489